Company: RNAC
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001453687-25-000099
Chunk: 107

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 8
Chunk 107
---
 3,030,053 2,344,017 Warrants to purchase common stock692,523 975,132 692,523 975,132 Series A Preferred Stock4,026,346 5,544,719 4,026,346 5,544,719 Series B Preferred Stock437,927 — 437,927 — Total7,493,477 7,260,062 8,186,849 8,863,868 

7. Fair Value Measurements

The following tables present the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2025 and December 31, 2024 (in thousands):June 30, 2025TotalLevel 1Level 2Level 3Assets:     Money market funds (included in cash equivalents)$39,933 $39,933 $— $— Total assets$39,933 $39,933 $— $— Liabilities:     Warrant liabilities$1,364 $— $— $1,364      Contingent value right liability$352,100 $— $— $352,100 Total liabilities$353,464 $— $— $353,464  December 31, 2024TotalLevel 1Level 2Level 3Assets:     Money market funds (included in cash equivalents)$39,088 $39,088 $— $— Total assets$39,088 $39,088 $— $— Liabilities:     Warrant liabilities$3,836 $— $— $3,836      Contingent value right liability$395,500 $— $— $395,500 Total liabilities$399,336 $— $— $399,336 

14

There were no transfers within the fair value hierarchy during the six months ended June 30, 2025 or the year ended December 31, 2024.Cash, Cash Equivalents, and Restricted CashAs of June 30, 2025 and December 31, 2024, money market funds were classified as cash and cash equivalents on the accompanying consolidated balance sheets as they mature within 90 days from the date of purchase.As of June 30, 2025